AHA 2016: Advances in the Management of Patients with Heart Failure

This discussion-based, CME program will feature imperative information for the treatment and management of patients with heart failure presented at the American Heart Association Scientific Sessions 2016 held in New Orleans, Louisiana. Predictors of heart failure, patient assessment techniques and risk-benefit considerations for patients, both in the initiation of treatment and as treatment progresses, will be discussed. The three expert faculty will review newly released clinical trial data, particularly those pertaining to novel targeted therapeutics. Updates on major outcomes trials and the impending effect on clinical practice will be assessed. After participating in this activity, healthcare professionals will gain insight into optimal, personalized treatment and management strategies as well as methods of improving outcomes in patients with heart failure.


This activity has been designed to meet the educational needs of allergists cardiologists, primary care physicians, and other healthcare professionals who care for patients with heart failure.


Upon completion of this activity, participants will be able to:

  1. Discuss patient assessment, comorbidities, and risk-benefit considerations for heart failure patients.
  2. Analyze current clinical trial data for recent targeted therapies presented at AHA 2016.
  3. Develop optimal therapeutic strategies to improve patient outcomes.


Mark Dunlap, MD
Professor of Medicine, Physiology, and Biophysics
Case Western Reserve University
Director, Heart Failure Section, Heart and Vascular
MetroHealth Medical Center
Cleveland, Ohio

Lee R. Goldberg, MD, MPH
Medical Director
University of Pennsylvania Heart Failure and Transplantation Program
Associate Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Mariell Jessup, MD
Professor of Medicine
University of Pennsylvania School of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Mark Dunlap, MD

Nothing to disclose.

Lee R. Goldberg, MD, MPH

Consultant/Advisor: Medtronic

Mariell Jessup, MD

Nothing to disclose.

Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Sandy Breslow; Alison Kemp; Leah Johnson; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.


CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.